<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15209">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02908880</url>
  </required_header>
  <id_info>
    <org_study_id>PSD-109</org_study_id>
    <nct_id>NCT02908880</nct_id>
  </id_info>
  <brief_title>MANTA Vascular Closure Device Clinical Study</brief_title>
  <acronym>MANTA</acronym>
  <official_title>Pivotal Clinical Study to Evaluate the Safety and Effectiveness of MANTA Vascular Closure Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Essential Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Essential Medical, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research study which tests the safety and effectiveness of a new vascular closure device to
      close the femoral access puncture that is created in patients who require this form of
      access in order to perform the planned procedure. The MANTA device is expected to seal the
      femoral access puncture in less than 1 minute. This may result in less blood loss and a
      shorter time to walking compared to alternative closure means. Use of the MANTA device in
      this study is experimental. All other parts of the procedure involve standard medical care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The MANTA device is a VCD intended for use in catheterization laboratories following
      percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery
      access route for large bore (10‐18F ID) interventional devices. The function of MANTA is to
      percutaneously close the puncture in the artery wall (arteriotomy) through which the
      catheters were inserted for the procedure.

      The study is being conducted o demonstrate the safety and effectiveness of MANTA in
      achieving hemostasis in femoral arterial access sites in subjects undergoing percutaneous
      transcatheter interventional procedures using a large-bore procedure sheath.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Hemostasis</measure>
    <time_frame>Time of Procedure</time_frame>
    <description>From time of MANTA sheath withdrawal until confirmed hemostasis which is approximately 10 minutes.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">263</enrollment>
  <condition>Femoral Arteriotomy Closure</condition>
  <arm_group>
    <arm_group_label>MANTA vascular closure device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label, single arm study using the MANTA device, developed by Essential Medical, Inc.. MANTA is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10-18F) interventional devices.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MANTA vascular closure device</intervention_name>
    <description>The appropriate size of MANTA closure device will be selected and used to for the closure of femoral arterial access sites following the use of 10-14F devices or sheaths or the use of 15-18F devices or sheaths.</description>
    <arm_group_label>MANTA vascular closure device</arm_group_label>
    <other_name>MANTA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Candidate for elective or planned (i.e., not emergent or urgent) percutaneous
             transcatheter interventional procedure via a 10-18F size retrograde common femoral
             artery approach (i.e., transcatheter aortic valve implantation [TAVI], endovascular
             aneurysm repair [EVAR], Impella® use)

          2. Vessel size would allow for access for the MANTA device as determined by baseline
             CTA: minimum vessel diameter 5mm for the 14F MANTA and 6mm for the 18F MANTA

          3. Eligible for sheath removal in the catheterization lab

          4. Age ≥21 years

          5. Understand and sign the study specific written informed consent form

          6. Able and willing to fulfill the follow-up requirements

          7. In the investigator's opinion, patient is suitable for the MANTA vascular closure
             device, conventional hemostasis techniques and participation in an investigational
             trial

        Exclusion Criteria:

          1. Known to be pregnant or lactating

          2. Immunocompromised or with pre-existing autoimmune disease

          3. Systemic infection or a local infection at or near the access site

          4. Significant anemia (hemoglobin &lt;10 g/DL, hematocrit &lt;30%)

          5. Morbidly obese or cachectic (BMI &gt;40 kg/m2 or &lt;20 kg/m2)

          6. Known bleeding disorder including thrombocytopenia (platelet count &lt;100,000
             cells/UL), thrombasthenia, hemophilia, or von Willebrand disease

          7. Allergy to bovine materials or any other device material, including collagen and/or
             collagen products, polyglycolic or polylactic acid, stainless steel or nickel

          8. Femoral artery puncture in target groin within the prior 14 days

          9. Previous iliofemoral intervention in region of access site, including but not limited
             to prior atherectomy, stenting, surgical or grafting procedures in the access area

         10. Patients who have undergone use of an intra-aortic balloon pump through the arterial
             access site within 30 days prior to the baseline evaluation

         11. Patients who are not mobile and are confined to a wheelchair or bed

         12. NYHA class IV heart failure

         13. Patients who have already participated in the IDE study

         14. Currently participating in another clinical trial of an unapproved investigational
             device or drug that has not concluded the follow-up period

         15. Patient cannot adhere to or complete the investigational protocol for any reason
             including but not limited to geographical residence, psychiatric condition or life
             threatening disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Wood, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Paul's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zvonimir Krajcer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's Episcopal</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angela Waltman</last_name>
    <email>angela@essmedclosure.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sam Nardone</last_name>
    <email>sam@essmedclosure.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington DC</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sosy Tatarian</last_name>
      <phone>202-877-3728</phone>
      <email>Sosy.Tatarian@medstar.net</email>
    </contact>
    <contact_backup>
      <last_name>Petros Okubagzi</last_name>
      <phone>202-877-2146</phone>
      <email>Petros.G.Okubagzi@Medstar.net</email>
    </contact_backup>
    <investigator>
      <last_name>Itsik Ben-Dor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gus Pichard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ron Waksman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lowell Satler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nelson Bernardo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Evanston Hospital</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jordan Keller</last_name>
      <email>jkeller@northshore.org</email>
    </contact>
    <investigator>
      <last_name>Ted Feldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mike Salinger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mayra Guerrero, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincent Heart Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Kingma</last_name>
      <phone>317-583-6319</phone>
      <email>barbara.kingma@theheartcenter.com</email>
    </contact>
    <contact_backup>
      <last_name>Melanie Wheeler</last_name>
      <email>melanie.wheeler@theheartcenter.com</email>
    </contact_backup>
    <investigator>
      <last_name>Andrew Sampson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Hermiller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farah Jarjous</last_name>
      <phone>313-916-4475</phone>
      <email>Fjarjou1@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Marvin Eng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>William O'Neill, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Susheel Kodali, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carrie Melgaard</last_name>
      <email>melgaac@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Samir Kapadia, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Wismer, RN, CRC II</last_name>
      <phone>610-402-9005</phone>
      <email>meghan_C.wismer@lvhn.org</email>
    </contact>
    <contact_backup>
      <last_name>Shannon Huffaker</last_name>
      <phone>610-402-7195</phone>
      <email>shannon_L.Huffaker@lvhn.org</email>
    </contact_backup>
    <investigator>
      <last_name>David Cox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jessica Vazquez, RN</last_name>
      <phone>215-707-3460</phone>
      <email>jessica.vazquez@tuhs.temple.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennie Wong, RN</last_name>
      <phone>215-707-5340</phone>
      <email>wongjk@tufs.temple.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Brian O'Neil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Howard Cohen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lankenau Heart Group</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Thome, M.S, CCRC</last_name>
      <phone>484-476-8570</phone>
      <email>ThomeL@mlhs.org</email>
    </contact>
    <investigator>
      <last_name>Paul Coady, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Avera Heart Hospital</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robin Farley, R.N.</last_name>
      <phone>605-977-5334</phone>
      <email>rfarley@ncheart.com</email>
    </contact>
    <contact_backup>
      <last_name>Patty Eisenbraun, R.N.</last_name>
    </contact_backup>
    <investigator>
      <last_name>J. Michael Bacharach, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wellmont Holston Valley Hospital</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandy Venable</last_name>
      <phone>423-230-5618</phone>
      <email>bvenable@mycva.com</email>
    </contact>
    <contact_backup>
      <last_name>Terrie Walker</last_name>
      <phone>423-230-5643</phone>
    </contact_backup>
    <investigator>
      <last_name>Chris Metzger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital - Texas Heart</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilberto Defreitas</last_name>
      <phone>713-798-6062</phone>
      <email>gilberto.defreitas@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Zvonimir Krajcer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Paul Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth Grieve</last_name>
      <phone>604-682-2344</phone>
      <phone_ext>64980</phone_ext>
      <email>egrieve@providencehealth.bc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Kim Ljubic</last_name>
      <phone>604-875-5601</phone>
      <email>kim.ljubic@vch.ca</email>
    </contact_backup>
    <investigator>
      <last_name>David Wood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Webb, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 9, 2017</lastchanged_date>
  <firstreceived_date>September 9, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MANTA, arterial closure device, large bore closure device</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data obtained will be used, without mentioning Subject PHI, to assess the results of the research, and the data could be used in the future with regard to this study or other studies. The data can be passed on to the health authorities for the purposes of registering the medical device.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
